

Anti-Human CD32 Antibody, Clone IV.3, FITC



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713

INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Antibodies

Mouse monoclonal IgG2b antibody
against human CD32, FITC-conjugated

Catalog #60012FI
#60012FI.1

100 Tests 20 µL/test
25 Tests 20 µL/test

Product Description

The IV.3 antibody reacts with human CD32 (FcγRII), an ~40 kDa type 1 transmembrane glycoprotein that mediates several functions including phagocytosis, cytotoxicity, immunomodulation and platelet aggregation. CD32 is encoded by three genes (A, B, C) and at least 6 isoforms are generated via alternative mRNA splicing, i.e., IIa1, IIa2, IIb1, IIb2, IIb3 and IIc. All isoforms are expressed by monocytes/macrophages, placental trophoblasts and endothelial cells. In addition, the IIb isoform is expressed by B cells, and the IIa isoform by platelets, granulocytes and, weakly, by B cells. Isoform IIc is expressed by NK cells and neutrophils. CD32 binds weakly to the Fc region of monomeric IgG but more strongly to IgG aggregates and immune complexes. These interactions can result in non-specific labeling in antibody-based detection and cell separation experiments and the IV.3 antibody may be employed as a blocking antibody to reduce non-specific binding. The IV.3 antibody binds most strongly to the IIa isoforms of CD32, with the epitope mapped to amino acids 132 - 137 [FSLHDP] in domain 2, within the ligand binding site.

Target Antigen Name:	CD32
Alternative Names:	FCR II, FcγRII
Gene ID:	2212
Species Reactivity:	Human
Host Species:	Mouse
Clonality:	Monoclonal
Clone:	IV.3
Isotype:	IgG2b, kappa
Immunogen:	K-562 human erythromyeloblastoid leukemia cell line
Conjugate:	FITC

Applications


Verified:	CellSep, FC
Reported:	FC
Special Applications:	This antibody clone has been verified for purity assessments of cells isolated with EasySep™ kits, including EasySep™ Human T Cell Enrichment Kit (Catalog #19051) and EasySep™ Human CD4+ T Cell Enrichment Kit (Catalog #19052).

Abbreviations: CellSep: Cell separation; ChIP: Chromatin immunoprecipitation; FA: Functional assay; FC: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence microscopy; IHC: Immunohistochemistry; IP: Immunoprecipitation; RIA: Radioimmunoassay; WB: Western blotting

Properties

Formulation:	Phosphate-buffered saline containing < 0.1% (w/v) sodium azide and < 0.1% (w/v) bovine serum albumin
Purification:	The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions.
Stability and Storage:	Product stable at 2 - 8°C when stored undiluted. Do not freeze. Protect product from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com .
Directions for Use:	For flow cytometry the suggested use of this antibody is 20 µL per 1 x 10 ⁶ cells in 100 µL volume or per 100 µL of whole blood. It is recommended that the antibody be titrated for optimal performance for each application.

Data



Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD32 Antibody, Clone IV.3, FITC (filled histogram) or Mouse IgG2b, kappa Isotype Control Antibody, Clone MPC-11, FITC (Catalog #60072FI; solid line histogram).

Related Products

For a complete list of antibodies, including other conjugates, sizes and clones, as well as related products available from STEMCELL Technologies, please visit our website at www.stemcell.com/antibodies or contact us at techsupport@stemcell.com.

References

1. Joulia R et al. (2015) Mast cells form antibody-dependent degranulatory synapse for dedicated secretion and defence. *Nat Commun* 6: 6174.
2. Sardjono CT et al. (2008) Epitope mapping of Fc gamma RIIa monoclonal antibodies. *Indonesian J Biotechnol* 13(1): 1030–7 (FC)
3. Xiao Z et al. (2008) Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. *Blood* 112(4): 1091–100. (FA/blocking)
4. Boruchov AM et al. (2005) Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. *J Clin Invest* 115(10): 2914–23. (FC)
5. van Sorge NM et al. (2003) Fc gamma R polymorphisms: Implications for function, disease susceptibility and immunotherapy. *Tissue Antigens* 61(3): 189–202.
6. Vely F et al. (1997) A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. *Hybridoma* 16(6): 519–28. (ELISA)
7. Schlossman SF et al. (Eds.). (1995) Binding heterogeneity within the CD32 panel of mAb. In: *Leucocyte Typing V* (pp. 832-35). New York: Oxford University Press.
8. Ierino FL et al. (1993) Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. *J Immunol* 150(5): 1794–803. (FC)
9. Tomiyama Y et al. (1992) Response of human platelets to activating monoclonal antibodies: Importance of Fc gamma RII (CD32) phenotype and level of expression. *Blood* 80(9): 2261–8.
10. Micklem KJ et al. (1990) Different isoforms of human FcRII distinguished by CDw32 antibodies. *J Immunol* 144(6): 2295–303. (FC, ICC, IHC, IP)
11. Looney RJ et al. (1986) Human monocytes and U937 cells bear two distinct Fc receptors for IgG. *J Immunol* 136(5): 1641–7.

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2016 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, Scientists Helping Scientists and EasySep are trademarks of STEMCELL Technologies Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.